Uncategorized
Amgen-AstraZeneca Partnered Asthma Drug Shows Rapid And Sustained Effect In Chronic Rhinosinusitis
Amgen and AstraZeneca’s Tezspire showed significant reductions in nasal polyp severity, congestion, and surgery need in CRSwNP patients in the Phase 3 WAYPOINT trial. read more
Bitcoin, Ethereum, XRP Consolidate After Trump Strategic Reserve Announcement
Prominent pseudonymous crypto trader Eugene Ng Sio is eyeing a measured approach to the current market conditions following President Trump’s strategic cryptocurrency reserve announcement that sent Bitcoin (CRYPTO BTC) read more
How To Earn $500 A Month From Best Buy Stock Ahead Of Q4 Earnings
Best Buy offers an annual dividend yield of 4.18%. So, how can investors exploit its dividend yield to pocket a regular $500 monthly? read more
‘Revenge Travel’ Slowdown Puts Damper On Trip.com’s Banner Year
Trip.com’s optimism for growth in 2025 will be amid a slowdown in post-pandemic revenge travel that spurred explosive growth in the past two years. read more
Marvell Vs. Broadcom: AI Arms Race Heats Up Ahead Of Earnings
Marvell and Broadcom are gearing up for earnings reports as AI spending accelerates. Both companies have distinct strategies and stand to benefit. Latest Ratings for AVGO Date Firm Action From To Mar 2022 Truist Securities Maintains Buy Mar 2022 JP Morgan Maintains Overweight Mar 2022 Morgan Stanley Maintains Overweight View More Analyst Ratings for AVGO…
Sunnova’s Solar Setback: Revenue Miss, Cash Flow Woes Sink Stock Over 50%
Sunnova Energy (NOVA) shares down premarket after Q4 & full-year results; revenue misses consensus, customer agreements & incentives up 43%, operational optimization to cut costs by $70M, guidance withdrawn. read more
Nomad Foods Surges On Q4 Earnings Beat; Raises Annual EPS Outlook
Nomad Foods shares rise in premarket trading after the company reported a 4.3% sales increase for Q4. Adjusted EPS of $0.46 surpassed estimates, while gross profit grew by 9%. The company also raised its adjusted EPS outlook for FY25. read more
EXCLUSIVE: Eco Wave Power 2024 Earnings: 22% Topline Growth, Narrows Operating Losses
NASDAQ: WAVE files annual report on Form 20-F with SEC for fiscal year ending Dec 31, 2024, recording first revenues of $168K from wave energy project and $225K in other income, with operating expenses down 7%, R&D up 4%, sales and marketing down 19.7%, and net loss increased. read more